StockNews.com Initiates Coverage on ContraFect with a Sell Rating

Recently, StockNews.com commenced analysis on ContraFect Corporation CFRX, a biotechnology firm dedicated to the creation of treatments for antibiotic-resistant and life-threatening infections. The coverage began on a Sunday with the issuance of a 'sell' recommendation for the company's shares. ContraFect's shares, which were listed at $0.05, were off to a modest start on the preceding Friday.

ContraFect's Financial Snapshot

The price spectrum of CFRX shares over the past year has seen a low of $0.05 and a peak of $15.76. Ailing to sustain a stable upward curve, the stock's 50-day moving average has hovered around $0.47, while the 200-day average scraped at $1.05. Currently, the firm's market capitalization is calculated at $535,000.00, with a PE ratio that stands null and a beta of 0.64, painting a cautious picture for potential investors.

When it comes to quarterly earnings, ContraFect delivered its report on Monday, August 14th, indicating a rather significant miss. Reporting an earnings per share value at ($1.94), the figure fell shy of the ($1.81) consensus estimate by ($0.13). Looking forward, analysts are anticipating an EPS of -3.44 for the ongoing fiscal year.

Investor Activity around ContraFect

A mix of hedge funds and investment firms have been actively dealing with shares of ContraFect. Envestnet Asset Management Inc. embarked on a new stake during the year's first quarter, amounting to approximately $41,000. Dimensional Fund Advisors LP expanded its shareholding by 62.9%, snagging an additional 43,564 shares. State Street Corporation STT, an established entity in financial services and bank holding based out of Boston, bolstered its position in ContraFect by 33.5% in the same period. The third quarter saw Two Sigma Investments LP take up a new stake valued at $39,000. Virtu Financial LLC VIRT, a provider of financial services and analytics from New York, augmented its stake by 48.9% in the fourth quarter, resulting in a new share total of 271,242 shares, valued at $26,000.

About ContraFect

With its headquarters situated in Yonkers, New York, ContraFect Corporation is immersed in Phase III clinical trials for its frontrunner program, Exebacase, which targets the treatment of Staphylococcus aureus infections.

StockNews, ContraFect, Coverage